MCNEL: A multi-scale convolutional network and ensemble learning for Alzheimer's disease diagnosis

Alzheimer's disease (AD) significantly threatens community well-being and healthcare resource allocation due to its high incidence and mortality. Therefore, early detection and intervention are crucial for reducing AD-related fatalities. However, the existing deep learning-based approaches often struggle to capture complex structural features of magnetic resonance imaging (MRI) data effectively. Common techniques for multi-scale feature fusion, such as direct summation and concatenation methods, often introduce redundant noise that can negatively affect model performance. These challenges highlight the need for developing more advanced methods to improve feature extraction and fusion, aiming to enhance diagnostic accuracy.

This study proposes a multi-scale convolutional network and ensemble learning (MCNEL) framework for early and accurate AD diagnosis. The framework adopts enhanced versions of the EfficientNet-B0 and MobileNetV2 models, which are subsequently integrated with the DenseNet121 model to create a hybrid feature extraction tool capable of extracting features from multi-view slices. Additionally, a SimAM-based feature fusion method is developed to synthesize key feature information derived from multi-scale images. To ensure classification accuracy in distinguishing AD from multiple stages of cognitive impairment, this study designs an ensemble learning classifier model using multiple classifiers and a self-adaptive weight adjustment strategy.

Extensive experiments on the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset validate the effectiveness of our solution, which achieves average accuracies of 96.67% for ADNI-1 and 96.20% for ADNI-2, respectively. The results indicate that the MCNEL outperforms recent comparable algorithms in terms of various evaluation metrics, demonstrating superior performance and robustness in AD diagnosis.

This study markedly enhances the diagnostic capabilities for AD, allowing patients to receive timely treatments that can slow down disease progression and improve their quality of life.